The Pharma Letter has published an article from partner Jane Dai, Ph.D. on considerations for biotech and pharma firms when making use of intellectual property from federally-funded programs.
The article discusses the CHIPS and Science Act of 2022, signed into law by President Biden in August, and the federal funding it will provide for research and innovation to various federal agencies. Dai goes on to present several considerations that pharma companies should consider from an IP perspective as a result of the significant boost in federal funding that will benefit pharmaceutical R&D through collaboration with universities as well as early-stage investment in startups.
Read the full article here >> (Subscription Required)
